HealthcareResearchScience

Growth Factor Therapy Shows Extended Heart Repair in Preclinical Study

A groundbreaking study demonstrates extended cardiac function improvement using platelet-derived growth factor-AB following myocardial infarction. The research, conducted in a clinically relevant porcine model, shows therapeutic benefits lasting 60 days post-treatment with comprehensive multi-modality assessment.

Breakthrough in Cardiac Regeneration

Researchers have demonstrated extended improvement in cardiac function using platelet-derived growth factor-AB (PDGF-AB) as a therapeutic agent for heart repair following myocardial infarction, according to a recent study published in npj Regenerative Medicine. The preclinical investigation, conducted in a porcine model that closely mimics human heart conditions, reportedly shows promising results for lasting cardiac recovery.

BiotechnologyHealthcareResearch

Study Reveals Organ-Specific Metabolic Responses to Fenofibrate Treatment in Rats

A comprehensive study examining fenofibrate’s effects reveals striking differences in how liver and kidney tissues respond to the medication. Researchers found significantly stronger metabolic activation in liver tissue compared to kidneys, with implications for understanding drug mechanisms and potential side effects.

Differential Organ Response to Common Medication

New research published in Scientific Reports reveals that fenofibrate, a commonly prescribed lipid-lowering medication, activates metabolic pathways differently in liver and kidney tissues, according to the study findings. The five-day rat exposure study demonstrated that while both organs showed responses to the drug, the liver exhibited significantly stronger activation of lipid metabolism pathways than the kidney.